Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sarah Derks

Showing results (21-30 of 62) with videos related to

Pageof 7
Sort By:
Plos One|June 2, 2026
Imaging strategies for follow-up during adjuvant nivolumab in esophageal cancer: A multicenter retrospective cohort studyTamara J Huizer, Anniek Strijdhorst, Laurens V Beerepoot, et al.
Therapeutic Advances in Medical Oncology|March 27, 2023
Comparing treatment and outcomes in advanced esophageal, gastroesophageal junction, and gastric adenocarcinomas: a population-based studyMarieke Pape, Pauline A J Vissers, Willemieke P M Dijksterhuis, et al.
Oncotarget|May 6, 2016
Abundant PD-L1 expression in Epstein-Barr Virus-infected gastric cancersSarah Derks, Xiaoyun Liao, Anna M Chiaravalli, et al.
Carcinogenesis|December 1, 2007
Integrated analysis of chromosomal, microsatellite and epigenetic instability in colorectal cancer identifies specific associations between promoter methylation of pivotal tumour suppressor and DNA repair genes and specific chromosomal alterationsSarah Derks, Cindy Postma, Beatriz Carvalho, et al.
Journal of Thoracic Disease|August 18, 2017
Non responders to neoadjuvant chemoradiation for esophageal cancer: why better prediction is necessaryChantal M den Bakker, Justin K Smit, Anna M E Bruynzeel, et al.
International Journal of Cancer|September 23, 2025
Adjuvant nivolumab after chemoradiotherapy and resection for patients with esophageal cancer: A real-world matched comparison of overall survivalRob H A Verhoeven, Steven C Kuijper, Marije Slingerland, et al.
Cancer Immunology Research|June 18, 2015
Epithelial PD-L2 Expression Marks Barrett's Esophagus and Esophageal AdenocarcinomaSarah Derks, Katie S Nason, Xiaoyun Liao, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|June 7, 2023
Neoadjuvant chemotherapy in older patients with gastric cancer undergoing surgery: a population-based cohort studyKammy Keywani, Alexander B J Borgstein, Wietse J Eshuis, et al.
Clinical Immunology (Orlando, Fla.)|April 18, 2026
A trophoblast glycoprotein specific 5 T4-Vδ2 bispecific T cell engager recruits Vγ9Vδ2-T cells for tumor-selective cytotoxicity across solid malignanciesMilon de Jong, Rok Žiberna, Myrthe Veth, et al.
Eclinicalmedicine|February 6, 2025
Real-world outcomes of the CROSS regimen in patients with resectable esophageal or gastro-esophageal junction adenocarcinoma: a nationwide cohort study in the NetherlandsHanneke van Laarhoven, Rob Verhoeven, Mark van Berge Henegouwen, et al.
Pageof 7

Showing results (21-30 of 62) with videos related to

Sort By:
Pageof 7
Plos One|June 2, 2026
Imaging strategies for follow-up during adjuvant nivolumab in esophageal cancer: A multicenter retrospective cohort studyTamara J Huizer, Anniek Strijdhorst, Laurens V Beerepoot, et al.
Therapeutic Advances in Medical Oncology|March 27, 2023
Comparing treatment and outcomes in advanced esophageal, gastroesophageal junction, and gastric adenocarcinomas: a population-based studyMarieke Pape, Pauline A J Vissers, Willemieke P M Dijksterhuis, et al.
Oncotarget|May 6, 2016
Abundant PD-L1 expression in Epstein-Barr Virus-infected gastric cancersSarah Derks, Xiaoyun Liao, Anna M Chiaravalli, et al.
Carcinogenesis|December 1, 2007
Integrated analysis of chromosomal, microsatellite and epigenetic instability in colorectal cancer identifies specific associations between promoter methylation of pivotal tumour suppressor and DNA repair genes and specific chromosomal alterationsSarah Derks, Cindy Postma, Beatriz Carvalho, et al.
Journal of Thoracic Disease|August 18, 2017
Non responders to neoadjuvant chemoradiation for esophageal cancer: why better prediction is necessaryChantal M den Bakker, Justin K Smit, Anna M E Bruynzeel, et al.
International Journal of Cancer|September 23, 2025
Adjuvant nivolumab after chemoradiotherapy and resection for patients with esophageal cancer: A real-world matched comparison of overall survivalRob H A Verhoeven, Steven C Kuijper, Marije Slingerland, et al.
Cancer Immunology Research|June 18, 2015
Epithelial PD-L2 Expression Marks Barrett's Esophagus and Esophageal AdenocarcinomaSarah Derks, Katie S Nason, Xiaoyun Liao, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|June 7, 2023
Neoadjuvant chemotherapy in older patients with gastric cancer undergoing surgery: a population-based cohort studyKammy Keywani, Alexander B J Borgstein, Wietse J Eshuis, et al.
Clinical Immunology (Orlando, Fla.)|April 18, 2026
A trophoblast glycoprotein specific 5 T4-Vδ2 bispecific T cell engager recruits Vγ9Vδ2-T cells for tumor-selective cytotoxicity across solid malignanciesMilon de Jong, Rok Žiberna, Myrthe Veth, et al.
Eclinicalmedicine|February 6, 2025
Real-world outcomes of the CROSS regimen in patients with resectable esophageal or gastro-esophageal junction adenocarcinoma: a nationwide cohort study in the NetherlandsHanneke van Laarhoven, Rob Verhoeven, Mark van Berge Henegouwen, et al.
Pageof 7